Biomarkers
By Dana Taylor
At the October 2020 conference of the European Society for Medical Oncology (ESMO), researchers presented information on new or recently approved targeted therapies and immunotherapies for lung cancer. Read More ›
In May 2020, the FDA approved Tabrecta, a new targeted therapy for the treatment of patients with metastatic non–small-cell lung cancer that is associated with the MET biomarker.
Read More ›
Non–small-cell lung cancer, or NSCLC, is the most common form of lung cancer, accounting for about 80% to 85% of all lung cancer cases in the United States.
Read More ›
By Kelsey Moroz
With her family history of cancers related to the BRCA mutation, Jamie Ledezma’s first pregnancy suddenly got very complicated when she learned she had triple-negative breast cancer. Read More ›
This special issue of CONQUER magazine is focused
on very innovative diagnostic tests that involve
biomarkers associated with cancer. For
many past decades we have provided the same
types of treatments for patients with cancer, basing
the treatments on the type of cancer the patient
had, and where it was in the body, such as
lung cancer or breast cancer. Read More ›
Understanding the specific biomarkers associated with each patient’s cancer helps to select the best therapy that targets that unique biomarker to improve the chance of survival for that patient. Read More ›
By Wayne Kuznar
Genetic testing, genomic testing, molecular profiling—how can you make sense of these terms to ensure you receive the best test and best treatment in this era of targeted therapies? A group of experts and patient advocates provide answers to these questions. Read More ›
By Wayne Kuznar
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker. Read More ›
By Dana Taylor
Breast cancer is the second
most common cancer
among women, but it
is important to remember
that men can also have breast
cancer. Recent advances in
therapy have led to the discovery
of specific biologic markers
(biomarkers) in cancer cells,
which has further led to the development
of drugs known as
targeted therapies. Read More ›
Patients with advanced lung cancer should be tested for the 5 most common biomarkers so they may receive the best treatment options for their disease. Read More ›